TFA
VYNE icon

Tobias Financial Advisors’s VYNE Therapeutics VYNE Stock Holding History

Tobias Financial Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-611
Closed -$1.65K – 90
2022
Q4 		$1.65K Buy
+611
New +$2.44K ﹤0.01% 81
2022
Q3 		– Sell
-611
Closed -$4K – 86
2022
Q2 		$4K Hold
611
– – ﹤0.01% 85
2022
Q1 		$7K Buy
+611
New +$7.26K ﹤0.01% 74
2021
Q1 		– Sell
-200
Closed -$23K – 71
2020
Q4 		$23K Hold
200
– – 0.01% 67
2020
Q3 		$24K Buy
+200
New +$23.3K 0.01% 67

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Tobias Financial Advisors's VYNE Position: Q1 2023 in Review

Tobias Financial Advisors sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 611 shares — an estimated $1.65K sold.

Tobias Financial Advisors first reported a position in VYNE in Q3 2020 and held it in 5 quarters. The position peaked at $24K in Q3 2020. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Tobias Financial Advisors reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tobias Financial Advisors sold 611 VYNE Therapeutics shares in Q1 2023, an estimated $1.65K.
  • Tobias Financial Advisors first reported a position in VYNE Therapeutics in Q3 2020 and held it in 5 quarters.
  • Tobias Financial Advisors's VYNE Therapeutics position peaked at $24K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Tobias Financial Advisors's 13F filing for Q1 2023, filed 24 Apr 2023.